The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CTMX | +208.18% | -49.85% | -12.89% | -74% |
| S&P | +15.06% | +95.03% | +14.29% | +235% |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.66M | -25.7% |
| Gross Profit | $18.31M | -25.7% |
| Gross Margin | 98.14% | 0.0% |
| Market Cap | $357.62M | 276.2% |
| Market Cap / Employee | $2.96M | 0.0% |
| Employees | 121 | -0.8% |
| Net Income | -$0.15M | 97.6% |
| EBITDA | -$0.94M | 88.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $49.04M | 13.4% |
| Accounts Receivable | $1.87M | -32.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.44M | -79.1% |
| Short Term Debt | $5.44M | 12.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 28.71% | 22.7% |
| Return On Invested Capital | 55.52% | 195.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15.78M | 19.7% |
| Operating Free Cash Flow | -$15.75M | 19.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 6.95 | 2.62 | 1.28 | 3.97 | -54.66% |
| Price to Book | -3.94 | -3.44 | -111.74 | 7.31 | -378.43% |
| Price to Sales | 0.79 | 0.60 | 0.38 | 2.08 | 139.77% |
| Price to Tangible Book Value | -3.69 | -3.22 | -25.62 | 7.77 | -411.46% |
| Enterprise Value to EBITDA | -1.42 | -0.48 | -0.71 | -151.01 | -5616.19% |
| Return on Equity | 108.2% | - | |||
| Total Debt | $10.60M | $9.39M | $8.15M | $6.89M | -41.38% |
CTMX earnings call for the period ending June 30, 2022.
CTMX earnings call for the period ending March 31, 2022.
CTMX earnings call for the period ending December 31, 2021.
CTMX earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
